Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 71

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 2
Chunk 71
---
’s largest shareholder. The transaction
was structured as a straight restricted common stock deal with no warrants. The Company issued 333,334 restricted shares of its common
stock, no par value (the “Common Stock”) at a purchase price of $3.00 per share, representing an 18% premium to the closing
share price of the Common Stock of $2.54 on the date of execution (the “Bayshore Financing”). The Company received the initial
payment of $1 million for the Bayshore Financing on May 20, 2025. On July 24, 2025, an additional $2 million was received, for the issuance
of 666,666 shares.

●
On July 17, 2025, we reported new preclinical results evaluating the effects of its lead candidate, Telomir-1, in a murine xenograft
model using P3 human prostate cancer cells. The data demonstrated that Telomir-1 reversed epigenetic silencing by DNA methylation of
the STAT1 gene, a tumor suppressor and immune response regulator, in a dose-dependent manner.

●
On July 18, 2025, we sold a total of 1,100,000 shares of our common stock, no par value, in block sales to institutional investors, at
an average price of $2.6045 per share (a premium to the prior day’s close), through its at-the-market equity offering facility.

15

●
On July 23, 2025, we reported new preclinical results showing that its lead compound, Telomir-1, restored mitochondrial function without
triggering oxidative stress or cell proliferation in human cells derived from a patient with Hutchinson-Gilford Progeria Syndrome (HGPS).

●
On August 7, 2025, we reported new preclinical data revealing that Telomir-1 potently inhibits three key histone demethylase enzymes-JMJD3,
FBXL10, and FBXL11-that regulate gene expression through epigenetic mechanisms. These enzymes are known to influence tumor progression,
immune response, metabolic function, and neuroinflammation.

●
On August 27, 2025, we sold a total of 350,000 shares of our common stock, no par value, in block sales to institutional investors, at
an average price of $1.95 per share, (a premium to the prior day’s close), through our at-the-market equity offering